Generic Name and Formulations:
Gadoversetamide 330.9mg/mL; soln for IV inj; preservative-free.
Indications for OPTIMARK:
For use with magnetic resonance imaging (MRI) in patients with abnormal blood brain barrier or abnormal vascularity of the brain, spine and associated tissues. For use with MRI to provide contrast enhancement and facilitate visualization of lesions with abnormal vascularity in the liver in patients who are highly suspect for liver structural abnormalities on computed tomography.
Give as bolus peripheral IV injection at a dose of 0.2mL/kg at a rate of 1–2mL/sec.
Chronic, severe renal disease (GFR <30mL/min/1.73m2) or acute renal injury.
Increase risk for nephrogenic systemic fibrosis in patients with impaired elimination of gadolinium-based contrast agents. Screen for acute kidney injury and other conditions that reduce renal function. Use lowest possible dose. Do not exceed recommended dose; allow sufficient period of time for elimination prior to re-administration. Sickle cell anemia and other hemoglobinopathies. Hemolytic anemias. History of asthma, allergy or other respiratory disorders. Anaphylactoid reactions possible; have emergency resuscitative equipment available. Monitor for hypersensitivity during and for several hours after injection; discontinue if occurs. Pregnancy (Cat.C). Nursing mothers: not recommended; discard breast milk up to 72hrs after injection.
Interference in serum iron, copper, zinc, and calcium measurements.
Gadolinium-based contrast agent.
Headache, vasodilation, taste perversion, dizziness, nausea, paresthesia; anaphylaxis (may be fatal).
Vials (5mL, 10mL, 15mL, 20mL)—10; Syringes (10mL, 15mL, 20mL, 30mL)—10
Sign Up for Free e-newsletters
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- A Witness to Letting Go: Nursing Care at the End of Life
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Modified XELIRI Noninferior to FOLFIRI for OS in Metastatic Colorectal Cancer
- Nabilone Improves Cancer-Associated Anorexia in Lung Cancer
- Direct-to-Consumer Genetic Test for Select BRCA Mutations Gets FDA Nod
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|